Nasopharyngeal Cancer - Pipeline Review, H2 2018 - ResearchAndMarkets.com

September 19, 2018

DUBLIN--(BUSINESS WIRE)--Sep 19, 2018--The “Nasopharyngeal Cancer - Pipeline Review, H2 2018” drug pipelines has been added to ResearchAndMarkets.com’s offering.

Nasopharyngeal Cancer - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Nasopharyngeal Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Nasopharyngeal Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Nasopharyngeal Cancer and features dormant and discontinued projects.

The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 18, 12, 1, 8, 5 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 6, 3, 6 and 1 molecules, respectively.

Nasopharyngeal Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Companies Featured

Advenchen Laboratories LLC Ambrx Inc arGEN-X BV Ascentage Pharma Group Corp Ltd Atara Biotherapeutics Inc AVEO Pharmaceuticals Inc BeiGene Ltd Biomics Biotechnologies Co Ltd Bristol-Myers Squibb Co CBT Pharmaceuticals Inc Celgene Corp Cell Medica Ltd F. Hoffmann-La Roche Ltd FLX Bio Inc Incyte Corp Jiangsu Hengrui Medicine Co Ltd MedImmune LLC Merck & Co Inc Merck KGaA Millennium Pharmaceuticals Inc Molecular Partners AG Neonc Technologies Inc Novartis AG Ono Pharmaceutical Co Ltd Otsuka Holdings Co Ltd Oxford Vacmedix UK Ltd Soricimed Biopharma Inc Systimmune Inc Tessa Therapeutics Pte Ltd Vectorite Biomedical Inc Viracta Therapeutics Inc

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/7fq2k3/nasopharyngeal?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180919005314/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Oncology Drugs



SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 09/19/2018 06:26 AM/DISC: 09/19/2018 06:26 AM


Update hourly